Cryoablation of Prostate & Kidney Cancer
A new, minimally invasive treatment that uses ice to destroy prostate and kidney cancer. Freezing tissue to -40°C temperature is instantly lethal to cancer, resulting in immediate cancer cell death.
Cryocare TCAP is approved by Medicare as a primary treatment for prostate and kidney cancer. It's also approved as a treatment for prostate cancer that recurs after any type of radiation.
Your physician inserts 6-8 slender probes into the prostate gland. Contained within each probe is argon gas cold enough to freeze the entire prostate. A warming catheter protects the urethra from the very cold temperatures. Ultrasound images allow your doctor to guide the probes to the best possible positions for destroying the cancer. Temperature sensors carefully monitor the process and precisely determine when target temperatures have been reached.
Your physician uses a minimally invasive laparoscopic approach through three to four tiny incisions to expose the kidney mass. Under direct vision and laparoscopic ultrasound, one or more cryo probes are placed into the cancer mass, which is then frozen killing the cancer cells. Patients are routinely sent home the day after surgery.
Why Consider Cryoablation?
- Minimally invasive prostate cancer treatment, not major surgery
- No radiation beams, no permanent radiation seeds, no radiation exposure
- Choice of general or spinal anesthesia
- Outpatient or overnight hospital stay
- Fast return to normal lifestyle
- Low risk of potential side effects (such as incontinence)
- Covered by Medicare and most insurance plans as a treatment for prostate cancer
- Recent published studies have demonstrated good long-term outcomes from doctors performing the Cryocare® TCAP TM prostate cancer treatment.